Business Context and Reporting Period
Company: Immatics N.V.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Immatics is a clinical-stage biopharmaceutical company developing T cell receptor (TCR)-based immunotherapies for solid tumors. The company operates two therapeutic modalities: autologous engineered TCR-T cell therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). It has no approved products for commercial sale and generates revenue solely through strategic collaboration agreements.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (€ millions) | 2023 (€ millions, Restated) |
|---|---|---|
| Revenue | 155.8 | 54.0 |
| Net Profit/(Loss) | 15.2 | (94.6) |
| Operating Result | (38.6) | (101.7) |
| Research & Development Expenses | (148.1) | (118.7) |
| Cash and Cash Equivalents | 236.7 | 218.5 |
| Total Financial Assets (Cash + Deposits) | 604.5 | 425.9 |
| Accumulated Deficit | (589.5) | (604.8) |
Note: The 2024 net profit was driven by significant non-operating financial income, including a €17.3 million gain from the change in fair value of warrant liabilities and €44.0 million in other financial income (interest and FX gains).
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased by €101.8 million (190%) compared to 2023. This was primarily due to:
- Higher revenue recognition from the Moderna collaboration (€62.8 million in 2024 vs. €5.4 million in 2023).
- Recognition of remaining deferred revenue following the termination of collaboration agreements with Genmab (€14.9 million), BMS IMA401 (€21.0 million), and BMS Allo (€33.1 million).
- Profitability Shift: The company reported a net profit of €15.2 million in 2024, reversing a net loss of €94.6 million in 2023. This turnaround is largely attributable to non-cash financial gains rather than operational profitability, as the operating result remained negative at €38.6 million.
- Capital Raises: The company raised approximately €343 million in gross proceeds through three public equity offerings in 2024 (January, October, and November).
- Restatement: The company restated its 2022 and 2023 financial statements to correct a material weakness regarding the recognition of deferred tax assets and liabilities related to tax loss carryforwards.
Guidance, Outlook, and Risks
Outlook and Milestones
- IMA203 (ACTengine): The lead candidate targeting PRAME in melanoma is in a Phase 3 trial ("SUPRAME"). Interim data analysis is expected in Q1 2026, with a Biologics License Application (BLA) submission targeted for Q1 2027 and market launch in Q3 2027.
- Manufacturing: A new 100,000 sq. ft. GMP manufacturing facility in Houston, Texas, is expected to commence GMP manufacturing for registration-enabling trials in 2025.
- Liquidity: Management believes existing cash and financial assets (€604.5 million) are sufficient to fund operations for at least the next 12 months.
Key Risks and Contingencies
- Material Weakness in Internal Controls: The company identified a material weakness in internal control over financial reporting related to the recognition, measurement, and disclosure of deferred tax assets/liabilities. This led to the restatement of prior years' financials. Management is implementing a remediation plan.
- Collaboration Terminations: The company terminated collaborations with Genmab, BMS (IMA401), and BMS (Allo) in 2024, resulting in the recognition of deferred revenue but eliminating future milestone and royalty potential from these specific agreements.
- Regulatory and Clinical Risks: As a clinical-stage company, success depends on the outcome of clinical trials (e.g., SUPRAME), regulatory approvals, and the ability to manufacture complex cell therapies.
- PFIC Status: There is a risk the company may be classified as a Passive Foreign Investment Company (PFIC) for U.S. tax purposes, which could have adverse tax consequences for U.S. investors.
Investor Verification Checklist
- Restatement Impact: Verify the specific adjustments made to the 2022 and 2023 financial statements regarding deferred tax liabilities and the status of the remediation plan for the material weakness.
- Revenue Quality: Analyze the composition of 2024 revenue to distinguish between recurring collaboration revenue and one-time gains from terminated agreements (Genmab, BMS).
- Cash Burn Rate: Assess the sustainability of the €604.5 million cash position against the projected costs of the Phase 3 SUPRAME trial and new manufacturing facility operations.
- Warrant Liability: Review the valuation of the warrant liability (€1.7 million as of Dec 31, 2024) and the impact of the €17.3 million gain on the net profit figure.
- Collaboration Pipeline: Confirm the status of the remaining active collaborations (Moderna, BMS main agreement) and the potential for future milestone payments.